A side-by-side comparison of two Healthcare investors: Catalio Capital Management (Power Score 82/100) and HSG (Power Score 85/100), both ranked among the most active firms tracked in this category.
| Catalio Capital Management | HSG | |
|---|---|---|
| Power Score™ | 82/100 | 85/100 |
| Assets Managed | $2B (the homepage prints "$2B In assets under management *as of 10/01/2025"; the raw date form is carried here because for a US filer 10/01/2025 reads as 1 October 2025) | Over US$61B (assets for institutional investors as of 30 June 2026, per hsgcap.com/about-us) |
| Founded | 2020 | 2005 |
| Headquarters | New York, NY | Hong Kong, China |
| Sectors | Healthcare, Biotech, Medical Devices, Diagnostics, Life Sciences, Data | Technology, Healthcare, Consumer |
Catalio Capital Management is an SEC-registered investment adviser (CRD 310374, SEC file 801-121976) that describes itself as focused on the full lifecycle of innovative healthcare investing, across private, public and credit markets. It runs four stated strategies: Private Equity and Venture Capital, investing in privately held innovative healthcare companies at all stages from inception to IPO; Structured Opportunities, providing senior-secured financing to healthcare innovators; Public Equities, a fundamental equity long/short strategy investing in global healthcare equities across innovative drugs, devices, diagnostics and data; and Co-Investments offering limited partners direct access to selected deals. The firm operates from New York, Washington DC and London, and states that it works with a network of more than 45 Venture Partners who hold equity interests across all Catalio strategies. It is a multi-strategy healthcare investment manager rather than a pure venture partnership.
View full Catalio Capital Management profile →HSG describes itself on its own About Us page as a venture capital and private equity firm, formerly known as Sequoia China, investing globally across technology, healthcare and consumer sectors. Its Chinese-language site describes the same three areas as 科技, 医疗 and 消费, and lists its investment stages as seed-stage, growth-stage, buyout, new-infrastructure and public-market investing (种子期投资, 成长期投资, 并购投资, 新基建投资, 公开市场投资). The firm states it has backed more than 1,800 companies, that over 190 of them have gone public and that over 140 have become unicorns. It states offices in Hong Kong, Shanghai, Beijing, Shenzhen, London, Tokyo and Singapore.
View full HSG profile →